These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

437 related items for PubMed ID: 16010439

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Characterization of a thymidylate synthase (TS)-inducible cell line: a model system for studying sensitivity to TS- and non-TS-targeted chemotherapies.
    Longley DB, Ferguson PR, Boyer J, Latif T, Lynch M, Maxwell P, Harkin DP, Johnston PG.
    Clin Cancer Res; 2001 Nov; 7(11):3533-9. PubMed ID: 11705873
    [Abstract] [Full Text] [Related]

  • 3. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
    Giovannetti E, Lemos C, Tekle C, Smid K, Nannizzi S, Rodriguez JA, Ricciardi S, Danesi R, Giaccone G, Peters GJ.
    Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
    [Abstract] [Full Text] [Related]

  • 4. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.
    van der Wilt CL, Backus HH, Smid K, Comijn L, Veerman G, Wouters D, Voorn DA, Priest DG, Bunni MA, Mitchell F, Jackman AL, Jansen G, Peters GJ.
    Cancer Res; 2001 May 01; 61(9):3675-81. PubMed ID: 11325838
    [Abstract] [Full Text] [Related]

  • 5. Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow.
    Das JR, Fryar-Tita EB, Green S, Southerland WM, Bowen D.
    Anticancer Res; 2007 May 01; 27(2):825-33. PubMed ID: 17465208
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Differences in the induction of DNA damage, cell cycle arrest, and cell death by 5-fluorouracil and antifolates.
    Backus HH, Pinedo HM, Wouters D, Kuiper CM, Jansen G, van Groeningen CJ, Peters GJ.
    Oncol Res; 2000 May 01; 12(5):231-9. PubMed ID: 11417748
    [Abstract] [Full Text] [Related]

  • 8. The role of pemetrexed in the treatment of colorectal cancer.
    Hochster H.
    Semin Oncol; 2002 Dec 01; 29(6 Suppl 18):54-6. PubMed ID: 12571812
    [Abstract] [Full Text] [Related]

  • 9. Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity.
    Mullany S, Svingen PA, Kaufmann SH, Erlichman C.
    Cancer Chemother Pharmacol; 1998 Dec 01; 42(5):391-9. PubMed ID: 9771954
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Mechanisms of action of FdUMP[10]: metabolite activation and thymidylate synthase inhibition.
    Bijnsdorp IV, Comijn EM, Padron JM, Gmeiner WH, Peters GJ.
    Oncol Rep; 2007 Jul 01; 18(1):287-91. PubMed ID: 17549381
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839).
    Azzariti A, Xu JM, Porcelli L, Paradiso A.
    Biochem Pharmacol; 2004 Jul 01; 68(1):135-44. PubMed ID: 15183125
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance.
    Xu JM, Azzariti A, Tommasi S, Lacalamita R, Colucci G, Johnston PG, Church SW, Paradiso A.
    Clin Colorectal Cancer; 2002 Nov 01; 2(3):182-8. PubMed ID: 12482336
    [Abstract] [Full Text] [Related]

  • 16. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs.
    Schultz RM, Chen VJ, Bewley JR, Roberts EF, Shih C, Dempsey JA.
    Semin Oncol; 1999 Apr 01; 26(2 Suppl 6):68-73. PubMed ID: 10598558
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Thymidylate synthase: a critical target for cancer chemotherapy.
    Rose MG, Farrell MP, Schmitz JC.
    Clin Colorectal Cancer; 2002 Feb 01; 1(4):220-9. PubMed ID: 12450420
    [Abstract] [Full Text] [Related]

  • 20. Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer.
    Markova B, Hähnel PS, Kasper S, Herbertz S, Schuler M, Breitenbuecher F.
    J Cancer Res Clin Oncol; 2012 Apr 01; 138(4):545-54. PubMed ID: 22203472
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.